Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032
Status: Archived
Whitman Walker Clinic
mi
from
Washington,
HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032
Status: Archived
Updated: 1/1/1970
Whitman Walker Clinic
mi
from
Washington,
HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032
Status: Archived
Duval County Health Department
mi
from
Jacksonville, FL
HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032
Status: Archived
Updated: 1/1/1970
Duval County Health Department
mi
from
Jacksonville, FL
HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032
Status: Archived
Miami-Dade County Health Department
mi
from
Miami, FL
HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032
Status: Archived
Updated: 1/1/1970
Miami-Dade County Health Department
mi
from
Miami, FL
HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032
Status: Archived
Multnomah County Health Department
mi
from
Portland, OR
HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032
Status: Archived
Updated: 1/1/1970
Multnomah County Health Department
mi
from
Portland, OR
HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032
Status: Archived
Allegheny Cancer Center at Allegheny General Hospital
mi
from
Pittsburgh, PA
HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032
Status: Archived
Updated: 1/1/1970
Allegheny Cancer Center at Allegheny General Hospital
mi
from
Pittsburgh, PA
HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032
Status: Archived
Richland County Health Department
mi
from
Colombia, SC
HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032
Status: Archived
Updated: 1/1/1970
Richland County Health Department
mi
from
Colombia, SC
HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032
Status: Archived
Public Health Seattle & King County
mi
from
Seattle, WA
HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032
Status: Archived
Updated: 1/1/1970
Public Health Seattle & King County
mi
from
Seattle, WA
Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients
Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients
Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Western Equine Encephalitis Vaccine
Phase 1 Study to Evaluate the Safety and Immunogenicity of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, In Healthy Adults
Status: Archived
U.S. Army Medical Research Institute of Infectious Diseases
mi
from
Fort Detrick, MD
Western Equine Encephalitis Vaccine
Phase 1 Study to Evaluate the Safety and Immunogenicity of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, In Healthy Adults
Status: Archived
Updated: 1/1/1970
U.S. Army Medical Research Institute of Infectious Diseases
mi
from
Fort Detrick, MD
Epidemiological Study in Children and Adolescents With Chronic Hepatitis B
A Cross-sectional, Multi-center, Epidemiological Study in Western and Asian Countries in Children and Adolescents With Chronic Hepatitis B
Status: Archived
Children's Medical Center of Dallas
mi
from
Dallas, TX
Epidemiological Study in Children and Adolescents With Chronic Hepatitis B
A Cross-sectional, Multi-center, Epidemiological Study in Western and Asian Countries in Children and Adolescents With Chronic Hepatitis B
Status: Archived
Updated: 1/1/1970
Children's Medical Center of Dallas
mi
from
Dallas, TX
Epidemiological Study in Children and Adolescents With Chronic Hepatitis B
A Cross-sectional, Multi-center, Epidemiological Study in Western and Asian Countries in Children and Adolescents With Chronic Hepatitis B
Status: Archived
University of Florida Gainesville
mi
from
Gainesville, FL
Epidemiological Study in Children and Adolescents With Chronic Hepatitis B
A Cross-sectional, Multi-center, Epidemiological Study in Western and Asian Countries in Children and Adolescents With Chronic Hepatitis B
Status: Archived
Updated: 1/1/1970
University of Florida Gainesville
mi
from
Gainesville, FL
Epidemiological Study in Children and Adolescents With Chronic Hepatitis B
A Cross-sectional, Multi-center, Epidemiological Study in Western and Asian Countries in Children and Adolescents With Chronic Hepatitis B
Status: Archived
Children's Hospital - Boston
mi
from
Boston, MA
Epidemiological Study in Children and Adolescents With Chronic Hepatitis B
A Cross-sectional, Multi-center, Epidemiological Study in Western and Asian Countries in Children and Adolescents With Chronic Hepatitis B
Status: Archived
Updated: 1/1/1970
Children's Hospital - Boston
mi
from
Boston, MA
Epidemiological Study in Children and Adolescents With Chronic Hepatitis B
A Cross-sectional, Multi-center, Epidemiological Study in Western and Asian Countries in Children and Adolescents With Chronic Hepatitis B
Status: Archived
Saint Vincent Healthcare Pediatric Specialty Clinics
mi
from
Billings, MT
Epidemiological Study in Children and Adolescents With Chronic Hepatitis B
A Cross-sectional, Multi-center, Epidemiological Study in Western and Asian Countries in Children and Adolescents With Chronic Hepatitis B
Status: Archived
Updated: 1/1/1970
Saint Vincent Healthcare Pediatric Specialty Clinics
mi
from
Billings, MT
Epidemiological Study in Children and Adolescents With Chronic Hepatitis B
A Cross-sectional, Multi-center, Epidemiological Study in Western and Asian Countries in Children and Adolescents With Chronic Hepatitis B
Status: Archived
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Epidemiological Study in Children and Adolescents With Chronic Hepatitis B
A Cross-sectional, Multi-center, Epidemiological Study in Western and Asian Countries in Children and Adolescents With Chronic Hepatitis B
Status: Archived
Updated: 1/1/1970
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Epidemiology Of Respiratory Virus Infections In Children
Epidemiology Of Respiratory Virus Infections In Children
Status: Archived
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
Epidemiology Of Respiratory Virus Infections In Children
Epidemiology Of Respiratory Virus Infections In Children
Status: Archived
Updated: 1/1/1970
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria
A Phase I, Randomized, Controlled Dosage-Escalation Study of the Safety and Reactogenicity of the EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria Administered Via Electroporation to Healthy Adults
Status: Archived
Emory University
mi
from
Atlanta, GA
EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria
A Phase I, Randomized, Controlled Dosage-Escalation Study of the Safety and Reactogenicity of the EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria Administered Via Electroporation to Healthy Adults
Status: Archived
Updated: 1/1/1970
Emory University
mi
from
Atlanta, GA
Computer-Assisted Tailored Cue-card Health [CATCH] Study
A Tailored Cue Card HIV/STI Intervention for High Risk Groups Pilot Study
Status: Archived
RTI International - Wake County Field Site
mi
from
Raleigh, NC
Computer-Assisted Tailored Cue-card Health [CATCH] Study
A Tailored Cue Card HIV/STI Intervention for High Risk Groups Pilot Study
Status: Archived
Updated: 1/1/1970
RTI International - Wake County Field Site
mi
from
Raleigh, NC
Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza
Phase 1 Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H2N3 (6-2) AA ca Recombinant (A/Swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H2N3 Infection in the Event of a Pandemic
Status: Archived
Strong Memorial Hospital (University of Rochester School of Medicine)
mi
from
Rochester, NY
Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza
Phase 1 Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H2N3 (6-2) AA ca Recombinant (A/Swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H2N3 Infection in the Event of a Pandemic
Status: Archived
Updated: 1/1/1970
Strong Memorial Hospital (University of Rochester School of Medicine)
mi
from
Rochester, NY
The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases
The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases
Status: Archived
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases
The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases
Status: Archived
Updated: 1/1/1970
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)
A Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating Pharmacokinetics and Safety of a Human Monoclonal Antibody (AVP-21D9) in Normal Healthy Volunteers
Status: Archived
ICON Development Solutions
mi
from
San Antonio, TX
Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)
A Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating Pharmacokinetics and Safety of a Human Monoclonal Antibody (AVP-21D9) in Normal Healthy Volunteers
Status: Archived
Updated: 1/1/1970
ICON Development Solutions
mi
from
San Antonio, TX
Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)
High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab
Status: Archived
Clinical Research Facility
mi
from
Ayer, MA
Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)
High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Ayer, MA
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Clinical Research Facility
mi
from
Birmingham, AL
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Birmingham, AL
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Memorial Hospital of Rhode Island
mi
from
Pawtucket, RI
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Memorial Hospital of Rhode Island
mi
from
Pawtucket, RI
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Center for Fertility and Women's Health
mi
from
New Britain, CT
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Center for Fertility and Women's Health
mi
from
New Britain, CT
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Abington Memorial Hospital
mi
from
Abington, PA
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Abington Memorial Hospital
mi
from
Abington, PA
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Clinical Research Facility
mi
from
Atlanta, GA
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Atlanta, GA
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Clinical Research Facility
mi
from
Oak Lawn, IL
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Oak Lawn, IL
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Clinical Research Facility
mi
from
Lexington, KY
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Lexington, KY
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Clinical Research Facility
mi
from
Springfield, MA
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Springfield, MA
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Clinical Research Facility
mi
from
Bismarck, ND
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bismarck, ND
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Clinical Research Facility
mi
from
Columbus, OH
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Columbus, OH
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Clinical Research Facility
mi
from
Portland, OR
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Portland, OR
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Clinical Research Facility
mi
from
Abington, PA
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Abington, PA
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Clinical Research Facility
mi
from
Rapid City, SD
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Rapid City, SD
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Clinical Research Facility
mi
from
Chattanooga, TN
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Chattanooga, TN
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Clinical Research Facility
mi
from
Dallas, TX
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Dallas, TX
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Clinical Research Facility
mi
from
Falls Church, VA
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Falls Church, VA
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Clinical Research Facility
mi
from
Marshfield, WI
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM1)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13â„¢ in Healthy Infants
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Marshfield, WI
Young Women's CoOp Study
Adapting the Women's CoOp for At-Risk Teens
Status: Archived
RTI International; Substance Abuse Treatment Evaluations and Interventions (SATEI) Community-Based Field Site - Durham
mi
from
Durham, NC
Young Women's CoOp Study
Adapting the Women's CoOp for At-Risk Teens
Status: Archived
Updated: 1/1/1970
RTI International; Substance Abuse Treatment Evaluations and Interventions (SATEI) Community-Based Field Site - Durham
mi
from
Durham, NC
Young Women's CoOp Study
Adapting the Women's CoOp for At-Risk Teens
Status: Archived
RTI International - Wake County Field Site
mi
from
Raleigh, NC
Young Women's CoOp Study
Adapting the Women's CoOp for At-Risk Teens
Status: Archived
Updated: 1/1/1970
RTI International - Wake County Field Site
mi
from
Raleigh, NC
Young Women's CoOp Study
Adapting the Women's CoOp for At-Risk Teens
Status: Archived
RTI International - Headquarters
mi
from
Research Triangle Park, NC
Young Women's CoOp Study
Adapting the Women's CoOp for At-Risk Teens
Status: Archived
Updated: 1/1/1970
RTI International - Headquarters
mi
from
Research Triangle Park, NC
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Newington, CT
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Newington, CT
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Atlanta, GA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Atlanta, GA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Metairie, LA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Metairie, LA